Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel
NASDAQ:SWTX

SpringWorks Therapeutics Q1 2025 Earnings Report

SpringWorks Therapeutics logo
Profile

SpringWorks Therapeutics EPS Results

Actual EPS
-$1.11
Consensus EPS
-$0.81
Beat/Miss
Missed by -$0.30
One Year Ago EPS
N/A

SpringWorks Therapeutics Revenue Results

Actual Revenue
$49.09 million
Expected Revenue
$64.19 million
Beat/Miss
Missed by -$15.10 million
YoY Revenue Growth
N/A

SpringWorks Therapeutics Announcement Details

Quarter
Q1 2025
Date
5/9/2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
6:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

SpringWorks Therapeutics' Q1 2025 Quarterly reportQuarterly report
(10-Q)

SpringWorks Therapeutics Earnings Headlines

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in ...
October 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/springworks-therapeutics-announces-publication-of-long-term-efficacy-and-safety-data-from-the-phase-3-defi-trial-of-ogsiveo-nirogacestat-in-adults-with-desmoid-tumors-in-the-journal-of-clinical-1035405698
SpringWorks Therapeutics Publishes Long-Term Efficacy and Safety Data for OGSIVEO® in Desmoid Tumors in Journal of Clinical Oncology
October 21, 2025  |  quiverquant.comQ
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 6 at 1:00 AM  |  Brownstone Research (Ad)
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data for OGSIVEO® in Treating Desmoid Tumors in Journal of Clinical Oncology
October 21, 2025  |  quiverquant.comQ
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
October 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/21/3169927/0/en/springworks-therapeutics-announces-publication-of-long-term-efficacy-and-safety-data-from-the-phase-3-defi-trial-of-ogsiveo-nirogacestat-in-adults-with-desmoid-tumors-in-the-journa.html
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
October 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/21/3169940/0/en/springworks-therapeutics-announces-publication-of-long-term-efficacy-and-safety-data-from-the-phase-3-defi-trial-of-ogsiveo-nirogacestat-in-adults-with-desmoid-tumors-in-the-journa.html
See More SpringWorks Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SpringWorks Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SpringWorks Therapeutics and other key companies, straight to your email.

About SpringWorks Therapeutics

SpringWorks Therapeutics (NASDAQ:SWTX), Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

View SpringWorks Therapeutics Profile
Earnings Tools